Why people with Hemophilia A of Mexican descent develop antibodies to factor VIII
Official title: Omic Approaches to Factor VIII Inhibitor Development in Hemophilia Patients of Mexican Descent
Funded at University of Texas Rio Grande Valley · NIH-11180308 · Data updated 2026-11-12
This project uses genetic and immune testing to learn why people with Hemophilia A of Mexican ancestry more often develop antibodies that block therapeutic factor VIII.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $673,590 |
| NIH project number | 5R01HL169763-02 |
| Project ID | NIH-11180308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with severe Hemophilia A of Mexican ancestry who can provide blood samples and medical history, whether or not they already have FVIII inhibitors.
✕Less likely to help
People without Hemophilia A, people with Hemophilia B, or those not of Mexican ancestry are unlikely to gain direct benefit from this project.
What this research studies
If you join, researchers will collect health information and blood samples from 200 people with severe Hemophilia A of Mexican ancestry and combine these with about 400 existing participants to create a large dataset. They will run whole-genome sequencing, mRNA sequencing, and CD4 T-cell functional tests to study immune reactions to therapeutic factor VIII. The team will record each person's F8 gene mutation type and whether they have FVIII antigen (CRM) to see how genetics and biology affect antibody risk. Visits will take place at clinics in the United States and Mexico for blood draws and clinical data collection.
Why it matters
Potential benefit: If successful, this work could help predict who is at high risk for inhibitors and guide safer, more personalized treatment choices.
How similar studies have gone: Previous genetic and immune studies have identified some risk factors for FVIII inhibitors, but combining whole-genome, transcriptome, and CD4 T-cell functional data in this specific population is largely novel.
Where this research is happening
-
University of Texas Rio Grande Valley
Edinburg, United States Active
Researchers
- Principal investigator: Howard, Tom Eugene — University of Texas Rio Grande Valley
- Study coordinator: Howard, Tom Eugene
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
Enhancing immune regulation in gene therapy for hemophilia (new approaches to safer treatment)
A patient-focused overview of a long-running NIH grant exploring how to make gene therapy for hemophilia safer by teaching the body’s immune system to tolerate the therapeutic protein.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Non-viral gene therapy approach to permanently fix hemophilia B
A new gene therapy approach aims to permanently correct hemophilia B without using viruses, potentially reducing bleeding events for people with this condition.
-
Hemophilia Point-of-Care Test Gets Regulatory Ready
A new point-of-care test for hemophilia A measures FVIII and emicizumab to help doctors manage bleeding risk quickly, with plans to obtain regulatory clearance.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.